1. 温州医科大学附属台州医院内分泌科,浙江,台州,317000
2. 温州医科大学附属第一医院内分泌科,浙江,温州,325000
扫 描 看 全 文
鲍灵珠, 沈飞霞, 高祖华. 温肾补虚方联合西药对亚临床甲状腺功能减退症患者血脂及血清IL-2、IL-10水平的影响[J]. 上海中医药杂志, 2019,53(1):70-72.
BAO Lingzhu, SHEN Feixia, GAO Zuhua. Effect of Wenshen Buxu Decoction combined with Western medicine on blood lipid and serum levels of IL-2 and IL-10 in treatment of subclinical hypothyroidism[J]. Shanghai Journal of Traditional Chinese Medicine, 2019,53(1):70-72.
鲍灵珠, 沈飞霞, 高祖华. 温肾补虚方联合西药对亚临床甲状腺功能减退症患者血脂及血清IL-2、IL-10水平的影响[J]. 上海中医药杂志, 2019,53(1):70-72. DOI: 10.16305/j.1007-1334.2019.01.018.
BAO Lingzhu, SHEN Feixia, GAO Zuhua. Effect of Wenshen Buxu Decoction combined with Western medicine on blood lipid and serum levels of IL-2 and IL-10 in treatment of subclinical hypothyroidism[J]. Shanghai Journal of Traditional Chinese Medicine, 2019,53(1):70-72. DOI: 10.16305/j.1007-1334.2019.01.018.
目的:观察温肾补虚方联合左甲状腺素钠治疗亚临床甲状腺功能减退症的临床疗效及对血脂、相关细胞因子水平的影响。 方法:将86例亚临床甲状腺功能减退症患者随机分为对照组与治疗组,每组43例。对照组采用左甲状腺素钠片治疗,治疗组在此治疗措施的基础上加用温肾补虚方。两组均治疗3个月,观察临床疗效,比较甲状腺功能、白介素-2(IL-2)、白介素-10(IL-10)、白介素-2受体(IL-2R)、血脂水平的变化情况。 结果:①治疗组、对照组总有效率分别为93.0% 、74.4%;组间临床疗效比较,差异有统计学意义(P,<,0.05)。②治疗前后组内比较,两组TSH水平较治疗前降低(P,<,0.05),FT,3,、FT,4,水平较治疗前升高(P,<,0.05);组间治疗后比较,TSH、FT,3,、FT,4,水平差异有统计学意义(P,<,0.05)。③治疗前后组内比较,两组TG、TC、LDL-C水平较治疗前降低(P,<,0.05),HDL-C水平较治疗前升高(P,<,0.05);组间治疗后比较,TG、TC、LDL-C、HDL-C水平差异有统计学意义(P,<,0.05)。④治疗前后组内比较,两组IL-2、IL-2R水平较治疗前降低(P,<,0.05),IL-10水平较治疗前升高(P,<,0.05);组间治疗后比较,IL-2、IL-10、IL-2R水平差异有统计学意义(P,<,0.05)。 结论:温肾补虚方联合左甲状腺素钠片治疗亚临床甲状腺功能减退症疗效满意,与单纯使用左甲状腺素钠片相比,能更好地改善患者的甲状腺功能,调节血脂及相关细胞因子水平。
Objective:To observe the clinical efficacy of Wenshen Buxu Decoction combined with levothyroxine sodium in the treatment of subclinical hypothyroidism (SCH) and its effect on blood lipids and related cytokine levels. MethodsA total of 86 SCH patients were randomly divided into treatment group and control group,43 cases in each group. The control group was treated with levothyroxine sodium tablets,and the treatment group was treated with Wenshen Bushu Decoction based on the treatment of the control group. The two groups were treated for 3 months. The clinical efficacy was observed and the interleukin-2 (IL-2),interleukin-10 (IL-10),interleukin-2 receptor (IL-2R) as well as the thyroid function related indicators including serum thyroid stimulating hormone (TSH),serum free triiodothyronine (FT,3,),serum free thyroxine (FT,4,),the blood lipids indexes including triglycerides (TG),total cholesterol (TC),high-density lipoprotein cholesterol (HDL-C),low-density lipoprotein cholesterol (LDL-C)]in the two groups were compared. Results:①The total effective rate of the treatment group had significantly statistical difference compared with that of the control group (93.02% vs 74.42%,P,<,0.05);②After treatment,the TSH level was decreased (P,<,0.05),while the serum FT,3, and FT,4, levels were increased (P,<,0.05),with statistic difference between the two groups (P,<,0.05).③After treatment,the serum TG,TC and LDL-C levels were decreased (P,<,0.05),while the HDL-C level was increased (P,<,0.05),with statistic difference between the two groups (P,<,0.05).④After treatment,the serum IL-10 levels were increased (P,<,0.05),and the IL-2 and IL-2R levels were decreased (P,<,0.05),with statistic difference between the two groups (P,<,0.05). Conclusion:Compared with the single application of levothyroxine sodium,Wenshen Buxu Decoction combined with levothyroxine sodium can ameliorate the thyroid function and regulate the levels of blood lipids and related cytokines for SCH patients.
亚临床甲状腺功能减退症左甲状腺素钠温肾补虚方血脂IL-2IL-10
SCHlevothyroxine sodiumWenshen Buxu Decoctionblood lipidIL-2IL-10
0
浏览量
120
下载量
0
CSCD
8
CNKI被引量
关联资源
相关文章
相关作者
相关机构